{"name":"Sigmoid Pharma","slug":"sigmoid-pharma","ticker":"","exchange":"","domain":"","description":"Sigmoid Pharma is a biopharmaceutical company focused on the development of innovative treatments in early clinical stages. With a pipeline of three drugs, including CyCol® capsules and Sandimmun® IV, the company is advancing its research in key therapeutic areas.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxPM1VqMkd4bW15LW1RM1FTNFEzNHktNWRhM2hXWUpmMkMtRnc0dEdnaUVoYm1lMEpEQlVQSjJZN2M2ZVd5RmNVRUhmTmpvc2k5eFFaZXQycUdONVVkQ0tucGJYNXJOajY1ZE9tczVIZUp5cUZhMjFWaUpSV2ptclN4ZGl6NmVidXc1ZmU0MzYxTUVfWUZveTVzOS16YXpXaUNVS0V6TUM5dFQwT1huMjRnYnJtQWdwMjNxLTNiMUQtSW1odlNFNWREbGY0Q0JvR2ZuZ2ZQajYxazVxQ1BXdnYwamZONEJ0RkNha1M1NGF1djZlZ0NKVGhiVG50RQ?oc=5","date":"2024-11-19","type":"pipeline","source":"PR Newswire","summary":"Celiac Disease Pipeline Grows as 25+ Key Pharma Companies Join the Fight for Innovative Treatments | DelveInsight - PR Newswire","headline":"Celiac Disease Pipeline Grows as 25+ Key Pharma Companies Join the Fight for Innovative Treatments | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQYTMyOXE3LUVQQnBEeElmbmZncW9jdFlmN1diaW93RnZIcENicFEtNWlnUUlGYTczV3UyOF83UGJVQk1lbGI3eWtEWVc1TWtUNk1RUzNHQVljRjN6cTFnODd5VnJJSUhzM1dTbldiNWVzQXdVN1NFeTF3aU9nenNCZ2pjaS1IT3NxN3FSTUtEZ1hrc3ROMmNpR2VGTU9yVjEyQWVIdnkxT25xMTI0WWt5d1NsWndVaFhwWFRFMWR3UVRBSGNNSWVZ?oc=5","date":"2024-09-03","type":"pipeline","source":"Healio","summary":"Filgotinib maintains remission, improves quality of life over 4 years in UC - Healio","headline":"Filgotinib maintains remission, improves quality of life over 4 years in UC","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE5fcUx2UDJpMWdhU09seFpBbUdjcVJacUVNVTBReTRnZTF5RkYtMVZJeG9MdDY5bk5nOHlCQkdTZ3VweEo3WENFVDBBd2VON0s1Zm9DYnZtZjJKaFFjWUN6LVlOR2s2NU1Yajg4LUtXUUI?oc=5","date":"2022-08-04","type":"pipeline","source":"BioSpace","summary":"BioSpace Movers & Shakers: Altos Labs, Vektor, Nautilus, Nurix & More - BioSpace","headline":"BioSpace Movers & Shakers: Altos Labs, Vektor, Nautilus, Nurix & More","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNWlBDcHREVXd4d0pacncxU0JyaVdxSmJLLU8wQl8xVEtxcUVDNVRsQ0Q0Ql8wMUZrYlR3eU9iWE1UR2hlZ05EeW15cFU5bXpZYTFwZjF5bDk4Um8wT1ppb1dFXzBBVlB2X29xdUgxVXRPT0tUNWJwLWhNbXgxbUlRVnV3NlRDZ1RuMk1sQXlRYjNWQQ?oc=5","date":"2021-11-11","type":"regulatory","source":"The Hearing Review","summary":"Neuromod Appoints Rosemarie Tully as COO - The Hearing Review","headline":"Neuromod Appoints Rosemarie Tully as COO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQWjJSOFU1NW1rbjhxRTlha2tYbEY3eWg2UV9Da25RNDE2TGtDVFRUWGxpbkVxZXZtU1RraWhDclB2VktGR0QxRkpUbUJfV1YyT3MxVEdNcjUxZEtVc2NYY3pfejhsc3N1dGtQcnhFNjBaYkxiN1NuUEFqakhjTjJjNXVvVTN1WUtMYndiTDJad0ZSTjRJRnVSUTdTUDAtaFJkVVVpRGlR?oc=5","date":"2021-04-13","type":"pipeline","source":"RTE.ie","summary":"Creditors meeting called for Sublimity Therapeutics - RTE.ie","headline":"Creditors meeting called for Sublimity Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxNRjFqRFFFZWM3bWtjRngyRDQ5dXlJSnN4UTZoMzBnVk5Vejl3VE1WUV9KMWNqcDJpSXFJWUZlaW5zb3Q5T0xvdW9aODhLeGk5eDZ0ck1haVM5bmw5R0FCVmFrWThUTnpaTXdPTW5aX3VDX0sxbWZ3TGNHMzdlUGZpa21ERHJQcFA1UU1NanRpUTJmZHBuVXRncndTOWFWZUZqWGFOQzFuMUxhU1IwN1IxV1V3bWZmVjJtUnhWVFZMQzN5NXNrSW5nWFloWW1RdkxqU0tGQTgwQ3owcE9HZnlOQVoyODdiUnlMT1BxNg?oc=5","date":"2018-08-28","type":"pipeline","source":"European Medical Journal","summary":"Entering a New Era of Patient-Reported Outcomes in Inflammatory Bowel Disease: Past, Present, and Future - European Medical Journal","headline":"Entering a New Era of Patient-Reported Outcomes in Inflammatory Bowel Disease: Past, Present, and Future","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPdjZEVXlrOWQ1a3J2eko4aVNMX1N5RFhiX1lWRWdiNTlHUnZSc2UxYkRaVGRDbFhmWGhseEpDTW90bW4wVHpiM2IzUklNVGNmaXloQ1lWWnM1czJ2VXVQckI0dVdmYWd1YVRhOWdjVF9LT3ZhWnpWeW5fOXc0azRmMVBoMDJ1R2ZrNjdPMEYydFdTVkpDeW1Td1hmQ3dXOTBP?oc=5","date":"2018-08-03","type":"pipeline","source":"Fierce Biotech","summary":"Chutes & Ladders—Cell Medica names Kite’s European chief as CEO - Fierce Biotech","headline":"Chutes & Ladders—Cell Medica names Kite’s European chief as CEO","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxQdGl1bmstWTQybXlRTHVWN0VvTFF3QU1mQ1lkNnRBWXpIUnVZUS1xS0RaSzJGLXpPR3lKTWZPU2JIQjV4RXhwa1dsTTdNZE1OSEgzY2RNbUpsTWZhd1RqSlBrdktOTkFjWHVLd29ELVFxdG8wQVJwVWo5YWlWNHcxc241ZzdqcXV3MmZxdThJT0dJUGlnQ0loSzNKdDMzT1Zyd1E?oc=5","date":"2017-04-16","type":"pipeline","source":"The Times","summary":"Dr Falk gives Sigmoid shot in the arm - The Times","headline":"Dr Falk gives Sigmoid shot in the arm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOa3RIeDlmUURPeVN1cnJFeHhTQnVtdFRKNEttb3ROcWpJQ1NxeS1ZejRDejRrTDMxdDEtci1UVTNtVWNzNnhxamVGZjFxYUVaaWpwVW1tVDR5ZkJsTlhzWGQ3NUo4NW1wUUt2eHQ1SUh6akxYS09xanF3dXlDYUZmV2RKOUV4RlVxMlpaYmlBb1cyWEJ1aG15eXgyTUNNTkV3cnA0STF5cVo1SUpUV2lIcWIta0ZWUQ?oc=5","date":"2016-05-19","type":"trial","source":"The Pharma Letter","summary":"Patients with left-sided colorectal cancer survive longer, study reveals - The Pharma Letter","headline":"Patients with left-sided colorectal cancer survive longer, study reveals","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE1CNGcwdm9sUnpPTFBtb0RPb2QyckthclotbTBjWkp4bjduNEtNdnFHdVZ4MWZqMEprTFVZOHYxU08wcEx6TDZMS0VLZ3R5VjBOWW9DVWJzazlYQnZPM29NbGI4SlZDTEZxd2JQbVoyZlVaWkNialI3VWhkMA?oc=5","date":"2015-11-10","type":"pipeline","source":"ScienceDirect.com","summary":"Targeted delivery of the hydroxylase inhibitor DMOG provides enhanced efficacy with reduced systemic exposure in a murine model of colitis - ScienceDirect.com","headline":"Targeted delivery of the hydroxylase inhibitor DMOG provides enhanced efficacy with reduced systemic exposure in a murin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxONFQxenU1REJ6WW9RYkZoa2FFRS1uWWo4SHFaNU5xX3ZFVVdpeEY2dE9SUFVQb2VOQmZ6VWpPM3FOZ3g0dFRfUWxnUjVTX1E2cHRMaXlpb1FxWk11QmU3T0hhNzZFYXhObHF1d2pjZFc5ZFlJcG1HLVlKT2lhN083alNVcWg5TlpNWmZ2VzNobHgyWVFwY1BJOFhtbTNDVEl2ZnY4MDdoSWtYUnhQMDcybjhlLUxmUEF5RzhJMHB5aFU2UWs4cGkyeUlWTTlYR2o3NENn?oc=5","date":"2015-07-17","type":"pipeline","source":"AstraZeneca","summary":"AstraZeneca completes agreement with Tillotts Pharma for Entocort - AstraZeneca","headline":"AstraZeneca completes agreement with Tillotts Pharma for Entocort","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZEFVX3lxTE5DVG1XS0VZVU5GY0Znb1V0UzFHSkpLbGhsNEVBc2czM1BOeXpBRGs1WGF4N000cnVHd0RNTEF3b29lZnZzVkRLSWU0WnpxbHFERWx4aThJNjdzWURlU1h6bHI5cEU?oc=5","date":"2009-11-04","type":"pipeline","source":"Genetic Engineering and Biotechnology News","summary":"BIO-Europe 2009 Day 3 - Genetic Engineering and Biotechnology News","headline":"BIO-Europe 2009 Day 3","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}